Smoking Cessation, Alcohol Drinking
Conditions
Brief summary
Alcohol misuse and smoking constitute two of the three leading preventable causes of death in the United States. The purpose of this research study is to develop an intervention designed to help people stop drinking alcohol and stop smoking at the same time.
Detailed description
Alcohol misuse and smoking constitute two of the three leading preventable causes of death in the United States. Reluctance to treat tobacco dependence among those with AUD is misguided as recent research suggests smoking cessation treatment can be effective, does not increase risk of relapse to alcohol, and may even improve rates of sobriety. There is strong evidence for the short-term efficacy for alcohol misuse and smoking of contingency management (CM). It is an intensive behavioral therapy that provides incentives (vouchers, money) to individuals misusing substances contingent upon objective evidence from drug use. Implementation of CM has been limited because of the need to verify abstinence multiple times daily using clinic based monitoring. The investigators recently developed a smart-phone application which allows a patient to video themselves several times daily while using a small CO monitor and to transmit the data to a secure server which has made the use of CM for outpatient smoking cessation portable and feasible. This mobile CM (mCM) approach paired with cognitive-behavioral counseling and pharmacological smoking cessation aids has been effective in reducing smoking. Thus, the purpose of this project is to develop a combined alcohol and smoking mCM intervention. The intervention will be developed in two successive cohorts of five participants, who will provide information on treatment acceptability and feasibility. A third cohort of participants (n=45) will participate in a randomized clinical trials to further examine feasibility and efficacy. The long term goal is to develop mCM procedures that will be used as part of a multi-component intervention to concurrently and effectively treat both alcohol misuse and smoking. As part of this project, the investigators will develop a multi-component telehealth alcohol and smoking mCM intervention. It will include mCM, cognitive-behavioral phone counseling, and standard smoking cessation pharmacotherapy. The work proposed in these aims will provide the first step toward implementation of an innovative approach that builds upon the power of mHealth technology to reduce the prevalence of both alcohol misuse and smoking.
Interventions
BEHAVIORALCognitive Behavioral Treatment
Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.
OTHERNicotine Replacement Therapy
Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or nicotine lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings
DRUGBupropion
All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
BEHAVIORALMobile Contingency Management
Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence.
BEHAVIORALMobile Monitoring
Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence.
Sponsors
Duke University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* currently meet criteria for DSM-5 mild to moderate alcohol use disorder (meeting 2-5 criteria for AUD) * have been engaging in hazardous drinking over the past month, defined as either exceeding a mean of 14 standard drinks/wk for men, 7 drinks/wk for women; or by consuming \>5 on at least one occasion in the last month for men, \>4 drinks on at least one occasion in the last month for women * currently smoke \>10 cigarettes a day, and have smoked for at least one year * can speak and write fluent conversational English * are willing to make an attempt to quit both alcohol and smoking
Exclusion criteria
* are expected to have unstable medication regimen during the study * are currently receiving non-study behavioral treatment for alcohol use disorder or smoking * have severe alcohol use disorder (meeting \>6 criteria for AUD or having alcohol withdrawal symptom criterion) * have AUD that is in early remission, with no symptoms evident over the past month * have experienced myocardial infarction in past 6 months * contraindication to nicotine replacement therapy with no medical clearance to participate in the study * use other forms of nicotine such as cigars, pipes, or chewing tobacco * are currently pregnant * have a primary psychotic disorder or current manic episode * have had substance use disorder (other than alcohol or nicotine) in the preceding 3 months * are currently imprisoned or in psychiatric hospitalization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Self-report Prolonged Abstinence From Smoking | 6 month follow-up | Participants will be asked to report on smoking since two weeks past quit date |
| Number of Participants Whose Prolonged Abstinence From Smoking is Bio-verified | 6 month follow-up | Self-reported prolonged abstinence (primary outcome) will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence. |
| Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use | 6 month follow-up | Participants will be asked to report on alcohol use since two weeks past quit date |
| Number of Participants Whose Prolonged Abstinence From Alcohol is Bio-verified | 6 month follow-up | Self-reported prolonged abstinence will be verified by breathalyzer. Breathalyzer data will be collected from participants who self-report prolonged abstinence. |
| Number of Participants Who Self-report Prolonged Dual Abstinence From Both Smoking and Alcohol | 6 month follow-up | Participants will be asked to report on smoking and alcohol use since two weeks past quit date |
| Number of Participants Whose Prolonged Dual Abstinence From Alcohol and Smoking is Bio-verified | 6 month follow-up | Self-reported prolonged abstinence from smoking will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence.Self-reported prolonged abstinence will be verified by breathalyzer. Breathalyzer data will be collected from participants who self-report prolonged abstinence. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use | 6 week follow-up (i.e., end of treatment visit) | Participants will be asked to report on alcohol use since two weeks past quit date |
| Number of Participants Whose Prolonged Abstinence From Alcohol is Bio-verified | 6 week follow-up (i.e., end of treatment visit) | Self-reported prolonged abstinence will be verified by breathalyzer. Breathalyzer data will be collected from participants who self-report prolonged abstinence. |
| Change in Number of Average Cigarettes Smoked Per Day | 6 month follow-up | Participants will self-report average number of cigarettes smoked in the past week and this will be compared to self-reported number of smoked in the week prior to quit. |
| Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking | 6 month follow-up | 7-day point prevalence abstinence is defined as no smoking in the prior 7 days. |
| Number of Participants Who Self-report Prolonged Abstinence From Smoking | 6 week follow-up (i.e., end of treatment visit) | Participants will be asked to report on alcohol use since two weeks past quit |
| Number of Participants Who Self-report 30 Day Point Prevalence Abstinence From Smoking | 6 week follow-up (i.e., end of treatment visit) | Participants will be asked to report on smoking since two weeks past quit date |
| Number of Smoking Quit Attempts | 6 week follow-up (i.e., end of treatment visit) | Participants will be asked to report the number of quit attempts made since quit date |
| Change in the Proportion of Days in Which Smoked Compared to Pre-quit Use | 6 month follow-up | Participants will self-report number of days smoked in the past 30 days and this will be compared to self-reported number of days smoked 30 days prior to quit. |
| Number of Participants Who Report 30 Day Point Prevalence Abstinence From Smoking | 6 month follow-up | 30-day point prevalence abstinence is defined as no smoking in the prior 30 days |
| Change in the Proportion of Days in Which Consumed Alcohol Compared to Pre-quit Use | 6 month follow-up | Participants will self-report number of days drank alcohol in the past 30 days and this will be compared to self-reported number of days drank alcohol in 30 days prior to quit. |
| Change in the Number of Standard Alcoholic Beverages Consumed Per Week Compared to Pre-quit Use | 6 month follow-up | Participants will self-report number of alcoholic beverages consumed in past 7 days and this will be compared to self-reported number of alcoholic beverages consumed in 7 days prior to quit. |
| Change in the Number of Heavy Drinking Episodes Compared to Pre-quit Use | 6 month follow-up | Participants will self-report number of heavy drinking episodes in the past 30 days and this will be compared to self-reported number of heavy drinking episodes in 30 days prior to quit. |
| Number of Participants Who Are Able to Achieve Recommended Drinking Limits (i.e., Less Than or Equal to 14 Drinks Per Week and Fewer Than 5 Drinks Per Day for Men; Less Than or Equal to 7 Days Per Week and Less Than 4 Drinks Per Day for Women) | 6 month follow-up | Participants will be asked to report on alcohol use in past week |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Tele-health Mobile Contingency Management Intervention This arm includes a tele-health intervention that combines evidence-based telephone cognitive behavioral treatment for alcohol and smoking cessation, smoking cessation pharmacotherapy (including nicotine replacement therapy and bupropion), and mobile contingency management treatment administered via a smart-phone based application (mobile CM).
Nicotine Replacement Therapy: Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings
Bupropion: All medically eligible participants will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
Cognitive Behavioral Treatment: Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.
Mobile Contingency Management: Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence. | 30 |
| Tele-health for Alcohol and Smoking Cessation This arm includes a tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same evidence-based telephone CBT for alcohol and smoking cessation, and smoking cessation pharmacotherapy as in the mCM intervention, but does not include mCM. Instead, participants receive monetary compensation for each assessment, regardless of abstinence.
Nicotine Replacement Therapy: Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings
Bupropion: medically eligible participants will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
Cognitive Behavioral Treatment: Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.
Mobile Monitoring: Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence. | 15 |
| Total | 45 |
Baseline characteristics
| Characteristic | Tele-health Mobile Contingency Management Intervention | Total | Tele-health for Alcohol and Smoking Cessation |
|---|---|---|---|
| Age, Continuous | 42.77 years STANDARD_DEVIATION 11.39 | 42.73 years STANDARD_DEVIATION 11.41 | 42.67 years STANDARD_DEVIATION 11.46 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 30 Participants | 45 Participants | 15 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 21 Participants | 32 Participants | 11 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 7 Participants | 9 Participants | 2 Participants |
| Region of Enrollment United States | 30 Participants | 45 Participants | 15 Participants |
| Sex: Female, Male Female | 6 Participants | 9 Participants | 3 Participants |
| Sex: Female, Male Male | 24 Participants | 36 Participants | 12 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 30 | 0 / 15 |
| other Total, other adverse events | 6 / 30 | 0 / 15 |
| serious Total, serious adverse events | 2 / 30 | 0 / 15 |
Outcome results
Primary
Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use
Participants will be asked to report on alcohol use since two weeks past quit date
Time frame: 6 month follow-up
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use | 4 Participants |
| Tele-health for Alcohol and Smoking Cessation | Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use | 0 Participants |
Primary
Number of Participants Who Self-report Prolonged Abstinence From Smoking
Participants will be asked to report on smoking since two weeks past quit date
Time frame: 6 month follow-up
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Participants Who Self-report Prolonged Abstinence From Smoking | 3 Participants |
| Tele-health for Alcohol and Smoking Cessation | Number of Participants Who Self-report Prolonged Abstinence From Smoking | 0 Participants |
Primary
Number of Participants Who Self-report Prolonged Dual Abstinence From Both Smoking and Alcohol
Participants will be asked to report on smoking and alcohol use since two weeks past quit date
Time frame: 6 month follow-up
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Participants Who Self-report Prolonged Dual Abstinence From Both Smoking and Alcohol | 1 Participants |
| Tele-health for Alcohol and Smoking Cessation | Number of Participants Who Self-report Prolonged Dual Abstinence From Both Smoking and Alcohol | 0 Participants |
Primary
Number of Participants Whose Prolonged Abstinence From Alcohol is Bio-verified
Self-reported prolonged abstinence will be verified by breathalyzer. Breathalyzer data will be collected from participants who self-report prolonged abstinence.
Time frame: 6 month follow-up
Population: This subset of participants self-reported prolonged abstinence from alcohol.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Participants Whose Prolonged Abstinence From Alcohol is Bio-verified | 4 Participants |
| Tele-health for Alcohol and Smoking Cessation | Number of Participants Whose Prolonged Abstinence From Alcohol is Bio-verified | 0 Participants |
Primary
Number of Participants Whose Prolonged Abstinence From Smoking is Bio-verified
Self-reported prolonged abstinence (primary outcome) will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence.
Time frame: 6 month follow-up
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Participants Whose Prolonged Abstinence From Smoking is Bio-verified | 2 Participants |
| Tele-health for Alcohol and Smoking Cessation | Number of Participants Whose Prolonged Abstinence From Smoking is Bio-verified | 0 Participants |
Primary
Number of Participants Whose Prolonged Dual Abstinence From Alcohol and Smoking is Bio-verified
Self-reported prolonged abstinence from smoking will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence.Self-reported prolonged abstinence will be verified by breathalyzer. Breathalyzer data will be collected from participants who self-report prolonged abstinence.
Time frame: 6 month follow-up
Population: This subset of participants self-reported dual abstinence from alcohol use and smoking.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Participants Whose Prolonged Dual Abstinence From Alcohol and Smoking is Bio-verified | 1 Participants |
| Tele-health for Alcohol and Smoking Cessation | Number of Participants Whose Prolonged Dual Abstinence From Alcohol and Smoking is Bio-verified | 0 Participants |
Secondary
Change in Number of Average Cigarettes Smoked Per Day
Participants will self-report average number of cigarettes smoked in the past week and this will be compared to self-reported number of smoked in the week prior to quit.
Time frame: 6 month follow-up
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Change in Number of Average Cigarettes Smoked Per Day | -8.56 cigarettes per day | Standard Deviation 7.45 |
| Tele-health for Alcohol and Smoking Cessation | Change in Number of Average Cigarettes Smoked Per Day | -5.30 cigarettes per day | Standard Deviation 6.5 |
Secondary
Change in the Number of Heavy Drinking Episodes Compared to Pre-quit Use
Participants will self-report number of heavy drinking episodes in the past 30 days and this will be compared to self-reported number of heavy drinking episodes in 30 days prior to quit.
Time frame: 6 month follow-up
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Change in the Number of Heavy Drinking Episodes Compared to Pre-quit Use | -9.22 heavy drinking episodes | Standard Deviation 10.22 |
| Tele-health for Alcohol and Smoking Cessation | Change in the Number of Heavy Drinking Episodes Compared to Pre-quit Use | -11.00 heavy drinking episodes | Standard Deviation 9.61 |
Secondary
Change in the Number of Standard Alcoholic Beverages Consumed Per Week Compared to Pre-quit Use
Participants will self-report number of alcoholic beverages consumed in past 7 days and this will be compared to self-reported number of alcoholic beverages consumed in 7 days prior to quit.
Time frame: 6 month follow-up
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Change in the Number of Standard Alcoholic Beverages Consumed Per Week Compared to Pre-quit Use | -7.53 drinks per week | Standard Deviation 17.54 |
| Tele-health for Alcohol and Smoking Cessation | Change in the Number of Standard Alcoholic Beverages Consumed Per Week Compared to Pre-quit Use | -13.9 drinks per week | Standard Deviation 17.72 |
Secondary
Change in the Proportion of Days in Which Consumed Alcohol Compared to Pre-quit Use
Participants will self-report number of days drank alcohol in the past 30 days and this will be compared to self-reported number of days drank alcohol in 30 days prior to quit.
Time frame: 6 month follow-up
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Change in the Proportion of Days in Which Consumed Alcohol Compared to Pre-quit Use | -9.67 drinking days per month | Standard Deviation 9.68 |
| Tele-health for Alcohol and Smoking Cessation | Change in the Proportion of Days in Which Consumed Alcohol Compared to Pre-quit Use | -10.3 drinking days per month | Standard Deviation 10.69 |
Secondary
Change in the Proportion of Days in Which Smoked Compared to Pre-quit Use
Participants will self-report number of days smoked in the past 30 days and this will be compared to self-reported number of days smoked 30 days prior to quit.
Time frame: 6 month follow-up
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Change in the Proportion of Days in Which Smoked Compared to Pre-quit Use | -9.22 days | Standard Deviation 10.98 |
| Tele-health for Alcohol and Smoking Cessation | Change in the Proportion of Days in Which Smoked Compared to Pre-quit Use | -4.70 days | Standard Deviation 11.5 |
Secondary
Number of Participants Who Are Able to Achieve Recommended Drinking Limits (i.e., Less Than or Equal to 14 Drinks Per Week and Fewer Than 5 Drinks Per Day for Men; Less Than or Equal to 7 Days Per Week and Less Than 4 Drinks Per Day for Women)
Participants will be asked to report on alcohol use in past week
Time frame: 6 month follow-up
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Participants Who Are Able to Achieve Recommended Drinking Limits (i.e., Less Than or Equal to 14 Drinks Per Week and Fewer Than 5 Drinks Per Day for Men; Less Than or Equal to 7 Days Per Week and Less Than 4 Drinks Per Day for Women) | 16 Participants |
| Tele-health for Alcohol and Smoking Cessation | Number of Participants Who Are Able to Achieve Recommended Drinking Limits (i.e., Less Than or Equal to 14 Drinks Per Week and Fewer Than 5 Drinks Per Day for Men; Less Than or Equal to 7 Days Per Week and Less Than 4 Drinks Per Day for Women) | 8 Participants |
Secondary
Number of Participants Who Report 30 Day Point Prevalence Abstinence From Smoking
30-day point prevalence abstinence is defined as no smoking in the prior 30 days
Time frame: 6 month follow-up
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Participants Who Report 30 Day Point Prevalence Abstinence From Smoking | 5 Participants |
| Tele-health for Alcohol and Smoking Cessation | Number of Participants Who Report 30 Day Point Prevalence Abstinence From Smoking | 1 Participants |
Secondary
Number of Participants Who Self-report 30 Day Point Prevalence Abstinence From Smoking
Participants will be asked to report on smoking since two weeks past quit date
Time frame: 6 week follow-up (i.e., end of treatment visit)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Participants Who Self-report 30 Day Point Prevalence Abstinence From Smoking | 2 Participants |
| Tele-health for Alcohol and Smoking Cessation | Number of Participants Who Self-report 30 Day Point Prevalence Abstinence From Smoking | 2 Participants |
Secondary
Number of Participants Who Self-report 30 Day Point Prevalence Abstinence From Smoking
Participants will be asked to report on smoking since two weeks past quit date
Time frame: 8 week follow-up (i.e., Session 7, end of monitoring visit)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Participants Who Self-report 30 Day Point Prevalence Abstinence From Smoking | 5 Participants |
| Tele-health for Alcohol and Smoking Cessation | Number of Participants Who Self-report 30 Day Point Prevalence Abstinence From Smoking | 2 Participants |
Secondary
Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking
Participants will be asked to report on smoking since two weeks past quit date
Time frame: 6 week follow-up (i.e., end of treatment visit)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking | 12 Participants |
| Tele-health for Alcohol and Smoking Cessation | Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking | 7 Participants |
Secondary
Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking
Participants will be asked to report on smoking since two weeks past quit date
Time frame: 8 week follow-up (i.e., Session 7, end of monitoring visit)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking | 13 Participants |
| Tele-health for Alcohol and Smoking Cessation | Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking | 9 Participants |
Secondary
Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking
7-day point prevalence abstinence is defined as no smoking in the prior 7 days.
Time frame: 6 month follow-up
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking | 6 Participants |
| Tele-health for Alcohol and Smoking Cessation | Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking | 2 Participants |
Secondary
Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use
Participants will be asked to report on alcohol use since two weeks past quit date
Time frame: 6 week follow-up (i.e., end of treatment visit)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use | 14 Participants |
| Tele-health for Alcohol and Smoking Cessation | Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use | 3 Participants |
Secondary
Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use
Participants will be asked to report on alcohol use since two weeks past quit
Time frame: 8 week follow-up (i.e., Session 7, end of monitoring visit)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use | 13 Participants |
| Tele-health for Alcohol and Smoking Cessation | Number of Participants Who Self-report Prolonged Abstinence From Alcohol Use | 1 Participants |
Secondary
Number of Participants Who Self-report Prolonged Abstinence From Smoking
Participants will be asked to report on alcohol use since two weeks past quit
Time frame: 8 week follow-up (i.e., Session 7, end of monitoring visit)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Participants Who Self-report Prolonged Abstinence From Smoking | 7 Participants |
| Tele-health for Alcohol and Smoking Cessation | Number of Participants Who Self-report Prolonged Abstinence From Smoking | 0 Participants |
Secondary
Number of Participants Who Self-report Prolonged Abstinence From Smoking
Participants will be asked to report on alcohol use since two weeks past quit
Time frame: 6 week follow-up (i.e., end of treatment visit)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Participants Who Self-report Prolonged Abstinence From Smoking | 11 Participants |
| Tele-health for Alcohol and Smoking Cessation | Number of Participants Who Self-report Prolonged Abstinence From Smoking | 0 Participants |
Secondary
Number of Participants Whose Prolonged Abstinence From Alcohol is Bio-verified
Self-reported prolonged abstinence will be verified by breathalyzer. Breathalyzer data will be collected from participants who self-report prolonged abstinence.
Time frame: 6 week follow-up (i.e., end of treatment visit)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Participants Whose Prolonged Abstinence From Alcohol is Bio-verified | 13 Participants |
| Tele-health for Alcohol and Smoking Cessation | Number of Participants Whose Prolonged Abstinence From Alcohol is Bio-verified | 1 Participants |
Secondary
Number of Smoking Quit Attempts
Participants will be asked to report the number of quit attempts made since quit date
Time frame: 6 week follow-up (i.e., end of treatment visit)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Smoking Quit Attempts | 2.25 smoking quit attempts | Standard Deviation 6.58 |
| Tele-health for Alcohol and Smoking Cessation | Number of Smoking Quit Attempts | 0.86 smoking quit attempts | Standard Deviation 0.38 |
Secondary
Number of Smoking Quit Attempts
Participants will be asked to report the number of quit attempts made since quit date
Time frame: 8 week follow-up (i.e., Session 7, end of monitoring visit)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Smoking Quit Attempts | 0.44 smoking quit attempts | Standard Deviation 1.03 |
| Tele-health for Alcohol and Smoking Cessation | Number of Smoking Quit Attempts | 4.11 smoking quit attempts | Standard Deviation 9.84 |
Secondary
Number of Smoking Quit Attempts
Participants will be asked to report the number of quit attempts made since quit date
Time frame: 6-month follow-up
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tele-health Mobile Contingency Management Intervention | Number of Smoking Quit Attempts | 2.29 smoking quit attempts | Standard Deviation 7.17 |
| Tele-health for Alcohol and Smoking Cessation | Number of Smoking Quit Attempts | 1.00 smoking quit attempts | Standard Deviation 1.64 |